Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05564390 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 321 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Interventions modified Trial arms changed: 39 → 41 · Site details revised at 1 of 355 sites Show 2 more changesShow less
    • Trial arms changed: 39 → 41
    • Site details revised at 1 of 355 sites
  2. Trial sites expanded: 350 → 354 locations
  3. Interventions: Allogeneic Hematopoietic Stem Cell Transplantation (Procedure), Azacitidine (Drug), Best Practice (Other), Biopsy Procedure (Procedure)… to Allogeneic Hematopoietic Stem Cell Transplantation (Procedure), Azacitidine (Drug), Azacitidine (Drug), Best Practice (Other), Biopsy… Study description expanded, about 738 words · Site details revised at 4 of 354 sites · Study arms: 39 to 41 Show 3 more changesShow less
    • Study description expanded, about 738 words
    • Site details revised at 4 of 354 sites
    • Study arms: 39 to 41
  4. Study sites: 350 to 354
  5. Site details revised at 1 of 350 sites
Show 45 earlier versionsHide 45 earlier versions
  1. Study sites: 349 to 350
  2. Site details revised at 2 of 349 sites
  3. Study description revised Site details revised at 29 of 349 sites Show 1 more changeShow less
    • Site details revised at 29 of 349 sites
  4. Site details revised at 2 of 349 sitesv313
  5. Site details revised at 4 of 349 sitesv312
  6. Site details revised at 4 of 349 sitesv311
  7. Study sites: 348 to 349v310
  8. Site details revised at 1 of 348 sitesv309
  9. Site contacts updated at 2 of 348 sitesv308
  10. Site details revised at 1 of 348 sitesv307
  11. Site details revised at 1 of 348 sitesv306
  12. Study sites: 347 to 348v305
  13. Study description shortened, about 1 wordv304 See this version in full on ClinicalTrials.gov ↗
  14. Site details revised at 1 of 347 sitesv303
  15. Study sites: 348 to 347v302
  16. Study description expanded, about 23 words Site details revised at 2 of 348 sitesv301 Show 1 more changeShow less
    • Site details revised at 2 of 348 sites

    See this version in full on ClinicalTrials.gov ↗

  17. Study sites revised (348)v300 See this version in full on ClinicalTrials.gov ↗
  18. Study sites revised (348)v299 See this version in full on ClinicalTrials.gov ↗
  19. Site contacts updated at 1 of 348 sitesv298
  20. Study sites: 347 to 348v297
  21. Site details revised at 1 of 347 sitesv296
  22. Site details revised at 1 of 347 sitesv295
  23. Site details revised at 2 of 347 sitesv294
  24. Re-verified, no change to tracked fieldsv293
  25. Site details revised at 1 of 347 sitesv292
  26. Site contacts updated at 3 of 347 sitesv291
  27. Site details revised at 1 of 347 sitesv290
  28. Site details revised at 2 of 347 sitesv289
  29. Site details revised at 1 of 347 sitesv288
  30. Site details revised at 1 of 347 sitesv287
  31. Site details revised at 1 of 347 sitesv286
  32. Site details revised at 1 of 347 sitesv285
  33. Site details revised at 1 of 347 sitesv284
  34. Site details revised at 1 of 347 sitesv283
  35. Site details revised at 2 of 347 sitesv282
  36. Re-verified, no change to tracked fieldsv281
  37. Study sites: 346 to 347v280
  38. Site details revised at 1 of 346 sitesv279
  39. Study sites revised (346)v278 See this version in full on ClinicalTrials.gov ↗
  40. Study sites: 347 to 346v277
  41. Site details revised at 1 of 347 sitesv276
  42. Site details revised at 1 of 347 sitesv275
  43. Study sites: 346 to 347v274
  44. Study sites: 345 to 346v273
  45. Re-verified, no change to tracked fieldsv272
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have or continue standard of care treatment with their doctor on the Tier Advancement Pathway (TAP).
Trial Details
NCT Number NCT05564390
Lead Sponsor National Cancer Institute (NCI)
Conditions Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Enrollment 2,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov